Resmetirom patent challenge 2022?

What patent challenge happened in 2022 for resmetirom?

In 2022, litigation and related filings began to focus on patents covering resmetirom (marketed as Rezdiffra), targeting the scope of pharmaceutical protection and whether certain exclusivities or claims could be avoided.

DrugPatentWatch tracks this type of “patent challenge” activity by listing relevant patents, legal status, and dispute timelines, including when challenges or court actions were filed in the run-up to potential competition.

You can see the specific resmetirom patent status and the 2022 legal events as they’re logged on DrugPatentWatch here: DrugPatentWatch – resmetirom patent information.

Who challenged the resmetirom patents in 2022, and what were they trying to achieve?

Patent challenges like these are typically aimed at one or more of the following:
- Invalidating particular patent claims (so they can’t block future products).
- Establishing non-infringement (the challenger’s product would not fall within the patent’s protected scope).
- Narrowing what is covered, so at least some patents can’t prevent entry.

DrugPatentWatch’s resmetirom listing is the quickest way to match the 2022 timing to the specific asserted patents and the case posture tracked for that period: DrugPatentWatch – resmetirom patent information.

Does the 2022 challenge mean generics or competitors could enter immediately?

A patent challenge filing in 2022 does not automatically mean a product can launch right away. Entry timing usually depends on:
- Whether the court rules in the challenger’s favor on the specific patents at issue.
- Whether other patents (not challenged, or still in force) remain barriers.
- How exclusivity periods and any stay/administrative rules affect launch timing.

The resmetirom patent status timeline on DrugPatentWatch shows what patents were still relevant and what happened after 2022: DrugPatentWatch – resmetirom patent information.

Which resmetirom patents were involved?

Resmetirom’s patent set can include different categories (method-of-use, composition, formulation, and related rights). Patent challenges in 2022 generally assert specific patents and specific claims rather than everything at once.

To see exactly which patents were implicated around 2022, use DrugPatentWatch’s resmetirom patent pages and legal-status entries: DrugPatentWatch – resmetirom patent information.

Where can I find the exact case filings or dates from 2022?

For the most direct mapping of “what happened in 2022,” DrugPatentWatch aggregates:
- Patent numbers and estates
- Stated legal events
- Timelines and status updates

Start here: DrugPatentWatch – resmetirom patent information.

---

Sources

1. DrugPatentWatch – resmetirom patent information